Prostate Cancer Therapeutics Market Size, Share to 2019

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Research has released the pharmaceutical report - “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”.

To Browse a Full Report with Toc: http://www.researchmoz.us/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-report.html

The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.

Scope

A brief introduction to prostate cancer, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.

In-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.

Comprehensive review of the pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.

Additional in-depth analysis of pipeline drug...